{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011145","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.675060+00:00","generated_at":"2026-05-17T14:20:54.382058+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Altimmune reports Q2 2025 net loss of $22.1M; positive pemvidutide MASH data reinforces differentiation","bullets":["Cash and investments $183.1M (up 39% from Dec 2024); net loss $22.1M ($0.27/sh) vs $24.6M ($0.35) Q2 2024.","Pemvidutide achieved up to 59.1% MASH resolution without worsening fibrosis, up to 34.5% fibrosis improvement, and up to 6.2% weight loss at 24 weeks.","New cT1 imaging data shows mean decreases of 145-148 ms (p<0.001), potentially class-leading in MASH trials.","End-of-Phase 2 FDA meeting targeted for Q4 2025; full 48-week data expected Q4.","Jerry Durso appointed Chairman; Mitchel Sayare remains director as part of board succession."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011145","json":"https://secwatch.observer/filing/0001558370-25-011145.json","markdown":"https://secwatch.observer/filing/0001558370-25-011145.md","text":"https://secwatch.observer/filing/0001558370-25-011145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000155837025011145/0001558370-25-011145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000155837025011145/alt-20250812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:20:54.382058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}